Top States: CA | DC | FL | GA | MA | NC | NJ | NY | OH | TX | WA |

Archive | Biotechnology RSS feed for this section

Americans Travel to Mexico for Stem Cell Stimulation Therapies and E+ Peptide Cancer Vaccine – Treatments Not Yet Offered in U.S.

By on Tue, 09 Aug 2011 in Biotechnology, Health, KIRKLAND, Wash., Press Releases, Travel, Washington State

KIRKLAND, Wash. (SEND2PRESS NEWSWIRE) — Many Americans – unsatisfied with traditional treatments for cancer, diabetes, osteoporosis, and other intractable diseases – are looking south for advanced remedies. ‘We’re struggling to keep up with demand,’ says Dr. Oscar E. Castro, head of Regenerative Cellular Therapy (RCT), of Puerto Penasco, Sonora, Mexico.

Continue Reading •

To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that ‘Sea of Troubles’

By on Tue, 07 Sep 2010 in Biotechnology, California, Medical, Press Releases, SAN MARINO, Calif.

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.

Continue Reading •

Lower Back Pain is Targeted by LifeModeler, Inc. with Newly Released Software

By on Tue, 23 Jun 2009 in Biotechnology, Press Releases

SAN CLEMENTE, Calif. (SEND2PRESS NEWSWIRE) — LifeModeler, Inc., the leading global provider of biomechanical human body simulation tools and services, has released LumbarSIM™, a new product that adds to its family of unique ‘virtual prototyping’ software. This latest innovation directly addresses the needs of orthopedic device manufacturers and surgeons seeking ways to respond to the growing numbers of patients experiencing lower back pain.

Continue Reading •

FDA Grants Epeius Biotechnologies’ Rexin-G A Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas

By on Tue, 08 Jul 2008 in Biotechnology, Press Releases

SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of all soft tissue sarcomas. This latest approval is the third clinical indication for which Rexin-G has been formally recognized by the FDA in the United States.

Continue Reading •

Epeius Biotechnologies Leads with Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma RandD Summit Conference in Boston

By on Thu, 18 Oct 2007 in Biotechnology, Press Releases

SAN MARINO, Calif. and BOSTON, Mass. – Oct. 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on ‘The Advent of Pathotropic Medicine for Cancer’ at the Global Pharma R&D Summit 2007 to be held in Boston.

Continue Reading •

Epeius Biotechnologies Affirms Leadership Role in The Development of Genetic Medicine

By on Wed, 11 Oct 2006 in Biotechnology, Press Releases

SAN MARINO, Calif. – Oct. 11 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company’s innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM).

Continue Reading •